MedTrace Logo

Intravenous Allopurinol in Heart Failure

NCT00181155 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2017-05-30

Study results available
· View outcomes & findings →

Summary

This study tests the hypothesis that allopurinol, a xanthine oxidase inhibitor, improves heart metabolism in patients with heart failure.

Conditions

  • Congestive Heart Failure

Interventions

DRUG

Allopurinol

intravenous infusion of allopurinol (300mg)

DRUG

Placebo

intravenous infusion of 50 ml dose of 5% dextrose

Sponsors & Collaborators

Principal Investigators

  • Robert G Weiss, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00181155 on ClinicalTrials.gov